INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015
Finite-lived intangible assets:
Gross Carrying Amount	$ 27,731.6		$ 28,186.7
Accumulated Amortization, Including Impairments	(8,680.6)		(7,411.6)
Net Carrying Amount	19,051.0		20,775.1
Total intangible assets
Gross Carrying Amount	30,016.4		30,494.6
Net Carrying Amount	21,335.8		23,083.0
Recognized impairment charge	215.0	$ 16.0	79.0
Tangible Asset Impairment Charges			23.0
Corporate brand
Finite-lived intangible assets:
Accumulated Amortization, Including Impairments	0.0		0.0
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	1,697.5		1,697.5
IPR&D
Finite-lived intangible assets:
Accumulated Amortization, Including Impairments	0.0		0.0
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	587.3		610.4
Total intangible assets
IPR&D write-off	14.0		28.0	$ 90.0	$ 12.0
Product brands
Finite-lived intangible assets:
Gross Carrying Amount	21,774.0		22,082.8
Accumulated Amortization, Including Impairments	(6,291.5)		(5,236.4)
Net Carrying Amount	15,482.5		16,846.4
Corporate brand
Finite-lived intangible assets:
Gross Carrying Amount	1,041.9		1,066.1
Accumulated Amortization, Including Impairments	(128.6)		(107.1)
Net Carrying Amount	913.3		959.0
Product rights
Finite-lived intangible assets:
Gross Carrying Amount	4,305.9		4,339.9
Accumulated Amortization, Including Impairments	(1,954.8)		(1,711.7)
Net Carrying Amount	2,351.1		2,628.2
Partner relationships
Finite-lived intangible assets:
Gross Carrying Amount	167.5		217.6
Accumulated Amortization, Including Impairments	(131.6)		(170.3)
Net Carrying Amount	35.9		47.3
Technology and other
Finite-lived intangible assets:
Gross Carrying Amount	442.3		480.3
Accumulated Amortization, Including Impairments	(174.1)		(186.1)
Net Carrying Amount	268.2		294.2
Ezogabine Retigabine
Total intangible assets
Recognized impairment charge			$ 27.0
Zelapar
Total intangible assets
Recognized impairment charge				$ 26.0
Pharming Group N.V., North American Commercialization Rights to Ruconest
Total intangible assets
Impairment loss	199.0
Goodwill impairment loss	$ 37.0